Pfizer looks past COVID with $43 billion deal for cancer drug maker Seagen
Reuters
Published Mar 13, 2023 06:54AM ET
Updated Mar 13, 2023 12:35PM ET
By Manas Mishra and Michael Erman
(Reuters) -Pfizer Inc on Monday struck a $43 billion deal to acquire Seagen Inc and its targeted cancer therapies as it braces for a steep fall in COVID-19 sales and generic competition for some top-selling drugs.
Seagen marks Pfizer (NYSE:PFE)'s largest purchase in a string of recent acquisitions utilizing a once-in-a-lifetime cash windfall from its COVID-19 vaccine and treatment. It will add four approved cancer therapies with combined sales of nearly $2 billion in 2022.
Washington-based Seagen is a pioneer of antibody-drug conjugates, which work like "guided missiles" designed to destroy cancer while sparing healthy cells.
Seagen's shares were trading up more than 16% at $200.93 on Monday, well below Pfizer's offer price of $229, signaling investor concern over a possible prolonged antitrust review. Pfizer shares were nearly 3% higher.
Pfizer's bid represents a 32.7% premium to Seagen's closing price on Friday.
"The Federal Trade Commission (FTC) clearance is sort of the open question at this point with regards to the deal," said Needham & Co analyst Ami Fadia, pointing to an overlap in bladder cancer treatments as an area the FTC could look into.
However, Fadia said there was less than a 50% chance of the FTC challenging the deal in court.
Pfizer, on a conference call to discuss the planned acquisition, acknowledged that antitrust regulators are likely to closely review the deal due to its size, but said the companies expect to be able to complete the transaction in late 2023 or early 2024.
PROTECTION FROM COMPETITION, REGULATORS
Adding Seagen helps Pfizer move into an area "that is more protected from a regulatory and patent perspective, and market dynamics," Chief Executive Albert Bourla said on the call.
Seagen is set to benefit from out-of-pocket healthcare spending caps for older Americans under President Joe Biden's Inflation Reduction Act (IRA), Bourla said, meaning more patients could gain access to the company's expensive treatments.
A focus on complex biotech medicines also provides a longer exclusivity on the market versus pills before becoming subject to government price limits under the IRA, he said. The U.S. Medicare program will be allowed to negotiate drug prices for the first time, with new prices for the initial 10 drugs selected starting in 2026.
Seagen's complicated drugs also make it more difficult for rivals to develop less expensive biosimilar versions, which could lengthen their profitability.
The latest deal comes as Pfizer seeks to mitigate an anticipated $17 billion hit to revenue by 2030 from patent expirations for top drugs, and a decline in demand for its COVID products.
Get The News You Want
Pfizer's COVID vaccine, which it shares with BioNTech, and oral antiviral treatment Paxlovid have brought in sales of more $90 billion through 2022.
The New York-based drugmaker said the Seagen deal and other recent acquisitions could generate more than $20 billion in combined sales in 2030.
Pfizer's recent deals include its purchase of Global Blood Therapeutics (NASDAQ:GBT) for $5.4 billion, migraine headache drug maker Biohaven Pharmaceutical Holding for $11.6 billion and a $6.7 billion buyout of drug developer Arena Pharmaceuticals.
Pfizer's oncology portfolio already boasts 24 approved therapies. The Seagen purchase would add Adcetris for lymphoma, Padcev for bladder cancers, Tivdak for cervical cancer and breast cancer treatment Tukysa.
Pfizer rival Merck & Co and Seagen were in advanced deal talks last year before they collapsed, according to reports.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.